银屑病关节炎的缓解:定义与预测因素
该研究纳入2000至2015年间银屑病关节炎(PsA)门诊随访的985例患者,采用复合标准定义缓解,发现18%至少一次达到缓解、9%维持至少连续两次访视的持续缓解;多因素分析显示较高BMI降低缓解几率,使用生物制剂提高缓解及持续缓解几率。
要点
- 18%的PsA患者至少达到一次缓解,9%达到至少连续两次访视的持续缓解。
- 较高BMI与较低的缓解几率相关(HR=0.96,p=0.012)。
- 使用生物制剂提高缓解几率(HR=1.48,p=0.034)及持续缓解几率(HR=1.76,p=0.020)。
核心结论
- PsA患者中18%至少一次达到缓解,9%达到至少连续两次访视的持续缓解。
- 较高BMI降低达到缓解的几率,使用生物制剂提高缓解及持续缓解的几率。
研究设计与样本
- 纳入2000至2015年间在PsA门诊随访的患者,按标准方案每6至12个月评估一次。
- 共纳入985例患者,57%为男性,平均年龄47.4岁。
- 缓解定义为无压痛或肿胀关节、无炎性背痛、无压痛附着点、BSA<1%的轻微皮肤受累、患者疼痛VAS<15、患者整体疾病活动VAS<20、HAQ<0.5。
- 对缓解标准不完整的访视采用插补法确定缓解状态。
- 采用多因素Weibull回归分析至缓解时间。
主要发现
- 175例(18%)患者至少一次达到缓解,92例(9%)达到至少连续两次访视的持续缓解。
- 较高BMI与较低缓解几率相关(HR=0.96,p=0.012)。
- 使用生物制剂与较高缓解几率相关(HR=1.48,p=0.034)。
- 使用生物制剂与至少连续两次访视的持续缓解几率相关(HR=1.76,p=0.020)。
- 以至少连续三次访视定义持续缓解时,生物制剂与持续缓解无显著关联。
关键数值与推荐
- 缓解定义:无压痛或肿胀关节、无炎性背痛、无压痛附着点、BSA<1%、疼痛VAS<15、整体疾病活动VAS<20、HAQ<0.5。
- 持续缓解定义为至少连续两次访视达到缓解。
临床怎么用
- 临床评估PsA缓解时可采用包含关节、附着点、皮肤、患者报告结局和功能的多维度复合标准。
- 对超重或肥胖的PsA患者,控制体重可能有助于提高达到缓解的几率。
- 生物制剂治疗与更高的缓解及持续缓解几率相关,可考虑用于追求缓解的治疗策略。
局限性
- 持续缓解的定义影响生物制剂与持续缓解的关联显著性(至少连续两次访视显著,至少连续三次访视不显著)。
- 对缓解标准不完整的访视采用插补法确定缓解状态。
- 研究为单中心门诊队列,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the frequency of remission defined by the absence of the various disease manifestations of psoriatic arthritis (PsA) and identify predictors for remission. METHODS: Patients followed at the PsA clinic between 2000 and 2015 were included. Patients are assessed at 6- to 12-month intervals according to a standard protocol. Remission was defined as a visit that patients had no tender or swollen joints, no inflammatory back pain, no tender entheseal sites, minimal skin involvement with BSA<1%, patient pain on visual analog scale (VAS) score of <15, patient global disease activity VAS score of <20, Health Assessment Questionnaire (HAQ) score <0.5. We used imputation approach to determine remission status for visits with incomplete criteria for each patient. RESULTS: Data from 985 patients (57% males, average age of 47.4 years) were included in this study. From 2000 to 2015, 175 (18%) patients achieved remission at least once and 92 (9%) experienced sustained remission over at least 2 consecutive visits. In a multivariate Weibull regression analysis for the time to remission, higher BMI was associated with lower chance of remission (HR = 0.96, p = 0.012), while the use of biologics increased the chance of achieving remission (HR = 1.48, p = 0.034). The effect of biologics was also significant on the chance of achieving sustained remission for 2 or more consecutive visits (HR = 1.76, p = 0.020). However, biologics were not significantly associated with sustained remission when it was defined based on 3 or more consecutive visits. CONCLUSION: Remission occurred at least once in 18% of the patients with PsA while sustained remission occurred in 9% of the study sample. Having higher BMI would reduce the achievement of remission. The use of biologic agents increased not only the chance of remission, but also the chance of sustained remission for at least 12 months.
引用
- Alharbi S, Ye JY, Lee KA, et al. Remission in psoriatic arthritis: Definition and predictors. Semin Arthritis Rheum. 2020. PMID: 32145969. doi:10.1016/j.semarthrit.2020.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。